Allergan's revenue beats on higher U.S. brand sales
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Mizuho Securities Reiterates Buy on Allergan (AGN) Following a 4Q Earnings Beat
February 23, 2016 7:04 AM ESTMizuho Securities maintained a Buy rating on Allergen (NYSE: AGN), and cut the price target to $330.00 (from $354.00), following the company's 4Q earnings report. AGN delivered a solid 4Q bottom line beat with revenues of $4.2B and EPS of $3.41 versus consensus estimates $4.2B and... More
